SMS Lifesciences India Ltd. (SMSLIFE) AI Stock Analysis

• Market Cap: ₹4.20B
• Dividend Yield: 0.11%
• Average Volume (3M): 127.00
• Price to Earnings (P/E): 22.5
• Beta (1Y): 0.62
• Revenue Growth: 1.36%
• EPS Growth: -14.54%
• Country: IN
• Employees: 574
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 20.18
• Shares Outstanding: 3,023,287
• 10 Day Avg. Volume: 254
• 30 Day Avg. Volume: 127
• PEG Ratio: 0.14
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 0.99
• P/FCF Ratio: 23.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ₹1,568.00 ▲(41.90% Upside)

SMS Lifesciences India Ltd. shows strong financial performance and technical momentum, which are the primary drivers of its stock score. However, the high P/E ratio and low dividend yield suggest potential overvaluation, which slightly tempers the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and demand for products, supporting long-term business expansion and stability.

Cash Flow Improvement

Improved cash flow growth enhances financial flexibility, enabling strategic investments and reducing reliance on external financing.

Profitability

High profitability margins reflect efficient operations and cost management, contributing to sustainable long-term financial health.

Negative Factors

Earnings Volatility

Fluctuating gross margins can indicate inconsistent cost control, which may impact profitability and financial predictability over time.

Cash Flow Volatility

Volatile cash flows can hinder strategic planning and investment, posing risks to operational stability and growth initiatives.

Reliance on Liabilities

Dependence on liabilities increases financial risk, especially in downturns, potentially affecting the company's ability to meet obligations.

SMS Lifesciences India Ltd. Business Overview & Revenue Model

Company Description

SMS Lifesciences India Ltd. (SMSLIFE) is a prominent pharmaceutical company based in India, specializing in the manufacture and supply of Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates primarily in the healthcare sector, focusing on the production of generics and specialty chemicals that cater to a wide range of therapeutic areas. SMSLIFE is committed to quality and innovation, with a robust portfolio that includes both bulk drugs and formulations, positioning itself as a key player in the global pharmaceutical supply chain.

How the Company Makes Money

SMS Lifesciences India Ltd. generates revenue primarily through the sale of its Active Pharmaceutical Ingredients (APIs) and intermediates to various pharmaceutical companies. The company operates on a B2B model, supplying its products to both domestic and international markets. Key revenue streams include direct sales of APIs, contract manufacturing services, and strategic partnerships with other pharmaceutical firms for co-development projects. Furthermore, SMSLIFE benefits from long-term contracts with clients, which provide a steady income stream. Their focus on quality and compliance with international standards has also opened doors for exports, contributing significantly to their earnings.

SMS Lifesciences India Ltd. Financial Statement Overview

Summary

SMS Lifesciences India Ltd. demonstrates robust financial health with growing profitability and efficient equity utilization. While the company shows stable cash flow and reasonable leverage, attention to cost management and cash flow consistency could further strengthen its financial position.

Income Statement

SMS Lifesciences India Ltd. shows a strong EBIT and EBITDA margin, with consistent revenue growth over the years. The net profit margin has been improving, indicating enhanced profitability. However, the volatility in gross profit margin suggests potential cost management issues.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio, indicating balanced leverage. The return on equity is solid, reflecting efficient use of equity capital. However, the equity ratio shows a moderate reliance on liabilities, which could pose risks in economic downturns.

Cash Flow

There is a noticeable improvement in free cash flow growth, and the operating cash flow to net income ratio is healthy, suggesting efficient cash conversion. However, historical inconsistencies in cash flow indicate potential volatility in operational cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.35B	3.45B	3.06B	3.16B	3.47B	2.66B
Gross Profit	1.03B	505.79M	962.44M	875.57M	875.42M	702.13M
EBITDA	458.85M	498.99M	349.41M	341.76M	489.11M	319.58M
Net Income	172.68M	201.09M	90.93M	114.63M	253.22M	135.57M
Balance Sheet
Total Assets	0.00	3.90B	3.91B	3.95B	3.57B	3.02B
Cash, Cash Equivalents and Short-Term Investments	15.08M	15.08M	5.70M	36.10M	33.56M	106.25M
Total Debt	0.00	864.09M	1.01B	1.00B	795.98M	646.86M
Total Liabilities	-2.12B	1.78B	1.97B	2.07B	1.92B	1.73B
Stockholders Equity	2.12B	1.97B	1.77B	1.64B	1.52B	1.29B
Cash Flow
Free Cash Flow	0.00	144.61M	34.38M	-3.38K	-623.94M	-3.87M
Operating Cash Flow	0.00	298.10M	243.06M	―	-112.41M	351.70M
Investing Cash Flow	0.00	-150.61M	-184.50M	-312.92M	-71.43M	-262.35M
Financing Cash Flow	0.00	-148.15M	-65.64M	168.88M	108.33M	-25.46M

SMS Lifesciences India Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1105.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSLIFE, the sentiment is Positive. The current price of 1105 is below the 20-day moving average (MA) of 1294.49, below the 50-day MA of 1208.50, and below the 200-day MA of 1204.68, indicating a bullish trend. The MACD of 56.78 indicates Negative momentum. The RSI at 63.61 is Neutral, neither overbought nor oversold. The STOCH value of 42.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SMSLIFE.

SMS Lifesciences India Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	76 Outperform	₹4.15B	36.60	―	―	21.55%	47.80%
SMSLIFE	69 Neutral	₹4.20B	22.48	―	0.11%	1.36%	-14.54%
SMSPHARMA	65 Neutral	₹24.95B	33.41	―	0.13%	11.91%	36.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LYKALABS	51 Neutral	₹2.89B	140.69	―	―	4.04%	-35.02%
NURECA	50 Neutral	₹2.68B	65.13	―	―	43.30%	―
BROOKS	41 Neutral	₹3.05B	22.24	―	―	18.67%	―

SMS Lifesciences India Ltd. Corporate Events

Haleos Labs Temporarily Withholds Dividends Pending KYC Updates

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, has announced a temporary withholding of dividend payments to shareholders who have not updated their KYC details as per SEBI requirements. This decision affects dividends declared at the company’s 19th Annual General Meeting for the financial year 2024-25, and payments will resume once shareholders comply with the KYC update requirements.

Haleos Labs Opens Special Window for Share Transfer Requests

Haleos Labs Limited has announced the opening of a ‘Special Window’ for the re-lodgment of physical share transfer requests, in compliance with a SEBI circular. This window, open from July 7, 2025, to January 6, 2026, allows shareholders to resubmit transfer requests, facilitating smoother transitions and ensuring regulatory compliance. The initiative reflects the company’s dedication to maintaining transparent and efficient shareholder communication, potentially enhancing stakeholder trust and operational efficiency.

SMS Lifesciences India Limited Announces Name Change at AGM

SMS Lifesciences India Limited, a company involved in the pharmaceutical industry, held its 19th Annual General Meeting (AGM) on September 30, 2025, through a video conference. The meeting was attended by 54 members, including promoters and public shareholders, and was conducted in compliance with regulatory guidelines from the Ministry of Corporate Affairs and SEBI. During the AGM, the company announced its name change to ‘HALEOS LABS LIMITED’ and is in the process of adopting the new name as per regulatory requirements. This change marks a significant shift in the company’s branding and may impact its market positioning and stakeholder relations.

SMS Lifesciences Announces Trading Window Closure Ahead of Financial Results

SMS Lifesciences India Ltd. has announced the closure of its trading window for designated and connected persons, effective from October 1, 2025, until 48 hours after the announcement of its financial results for the quarter and half-year ending September 30, 2025. This move is in compliance with SEBI’s regulations on insider trading and reflects the company’s adherence to governance standards, potentially impacting stakeholders by ensuring transparency and fairness in trading activities.

SMS Lifesciences Announces Dividend Record Date and Launches Shareholder Engagement Campaign

SMS Lifesciences India Ltd. has announced the record date for its 2024-25 dividend as September 24, 2025, with the dividend payment subject to shareholder approval at the upcoming AGM on September 30, 2025. Additionally, the company has launched the ‘Saksham Niveshak’ campaign to engage shareholders in updating KYC details and claiming unclaimed dividends, aligning with regulatory compliance and investor empowerment initiatives.